# RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study

> **NCT07065435** · PHASE2 · RECRUITING · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 74 (estimated)

## Conditions studied

- HER2 + Breast Cancer

## Interventions

- **DRUG:** Disitamab Vedotin (RC48)
- **DRUG:** Bevacizumab
- **DRUG:** Pyrotinib

## Key facts

- **NCT ID:** NCT07065435
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-01
- **Primary completion:** 2025-12-01
- **Final completion:** 2026-01-01
- **Target enrollment:** 74 (ESTIMATED)
- **Last updated:** 2025-07-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07065435

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07065435, "RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07065435. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*